To review a 50-year experience with total pelvic exenteration for treatment of advanced pelvic cancer.
Retrospective study with 100% follow-up.
Two hundred thirty-two patients referred for treatment of advanced pelvic cancer who underwent total pelvic exenteration.
Main Outcome Measures:
Rates of operative mortality, complications, recurrence, and 5-year survival.
The morbidity rate was 45%. The operative death rate was 14% during the 50-year period, but decreased from 16.8% in the first three decades to 10% thereafter. Eighty-nine patients (38%) had recurrences. The overall 5-year survival rate was 42%.
Operative mortality and morbidity have declined over 50 years, largely because of proper patient selection, increasing experience, and advances in perioperative care. Exenteration has a major role in the treatment of advanced pelvic cancer.(Arch Surg. 1994;129:390-396)
Lopez MJ, Standiford SB, Skibba JL. Total Pelvic ExenterationA 50-Year Experience at the Ellis Fischel Cancer Center. Arch Surg. 1994;129(4):390–396. doi:10.1001/archsurg.1994.01420280062008
Customize your JAMA Network experience by selecting one or more topics from the list below.